As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > COMMENTARY
COMMENTARY
- Barker on Drugs (8)
September 9, 2002
- Barkers on Drugs (7)
July 29, 2002
- BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
- BARKER ON DRUGS(5)
June 3, 2002
- BARKER ON DRUGS(4)
April 22, 2002
- Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
- BARKER ON DRUGS (3)
March 11, 2002
- BARKER ON DRUGS
February 18, 2002
- Comarketing as a Marketing Strategy Option -1-
January 21, 2002
- Comarketing as a Marketing Strategy Option -2-
January 21, 2002
- Barker on Drugs (1)
January 14, 2002
- Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan
July 9, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-
May 21, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -1-
May 21, 2001
- Forecasting JapaneseDrug Industry Growth in FY2001
March 26, 2001
- -1-
February 26, 2001
- -2-
February 26, 2001
- -1-
February 5, 2001
- -2-
February 5, 2001
- Advanced Technology and Segmentation of Companies
January 15, 2001
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…